John M. Kane, MD

The Zucker Hillside Hospital, Northwell Health, Department of Psychiatry, Glen Oaks, New York; Department of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York; Feinstein Institutes for Medical Research, Institute of Behavioral Science, Manhasset, New York; Corresponding author: John M. Kane, MD, Senior Vice President, Behavioral Health Services, Zucker Hillside Hospital, Northwell Health, 75-59 263rd St, Glen Oaks, NY 11004 ([email protected]).

DELETE Evaluating the Evidence

Injectable Antipsychotics in Schizophrenia

September 30, 2016

Read the recommendations of experts on the use of long-acting injectable antipsychotic medications in patients with schizophrenia.

Christoph U. Correll, Leslie Citrome, Peter M. Haddad, et al

Review Article

Benign Ethnic Neutropenia & Clozapine Use

July 27, 2016

Read a full review examining whether Benign Ethnic Neutropenia (BEN) should prevent treatment with clozapine.

Peter Manu, Nilofar Sarvaiya, Liliana M. Rogozea, et al

Original Research

Clozapine and Risperidone in Moderately Refractory Schizophrenia: A 6-Month Randomized Double-Blind Comparison

May 25, 2016

Nina R. Schooler, Stephen R. Marder, K. N. R. Chengappa, et al

Letter to the Editor

Dr Nielsen and Colleagues Reply

December 23, 2015

Jimmi Nielsen, Peter Manu, John M. Kane, et al

Article

Frequency and Correlates of DSM-5 Attenuated Psychosis Syndrome in a Sample of Adolescent Inpatients With Nonpsychotic Psychiatric Disorders

November 25, 2015

Miriam Gerstenberg, Marta Hauser, Aseel Al-Jadiri, et al

ASCP Corner

Recommendations for the Monitoring of Serum Concentrations of Antipsychotic Drugs in the Treatment of Schizophrenia

September 23, 2015

Leonardo V. Lopez, John M. Kane

Educational Activity

Making the Link Between Science and Symptoms in Schizophrenia

June 24, 2015

John M. Kane, Christoph U. Correll

Original Research

The RAISE: First-Episode Psychosis

March 25, 2015

Read an article describing The RAISE Early Treatment Program for First-Episode Psychosis, the background and study design of the program.

John M. Kane, Nina R. Schooler, Patricia Marcy, et al

Educational Activity

The Role of NMDA Receptors in Schizophrenia

January 28, 2015

John M. Kane

Educational Activity

Attitudinal Barriers to Prescribing LAI Antipsychotics in the Outpatient Setting: Communicating With Patients, Families, and Caregivers

December 24, 2014

John M. Kane

Clinical and Cost Implications of Treating Schizophrenia: Safety, Efficacy, Relapse Prevention, and Patient Outcomes

InfoPacks

Clinical and Cost Implications of Treating Schizophrenia: Safety, Efficacy, Relapse Prevention, and Patient Outcomes

August 26, 2014

John M. Kane, Christoph U. Correll, Philip D. Harvey, et al

Original Research

Aripiprazole Once-Monthly in the Acute Treatment of Schizophrenia: Findings From a 12-Week, Randomized, Double-Blind, Placebo-Controlled Study

August 19, 2014

John M. Kane, Timothy Peters-Strickland, Ross A. Baker, et al

« 1 2 3 4 5 … 11 »